FDA approves first over-the-counter birth control pill

In a landmark decision, federal regulators have approved the first over-the-counter birth control pill in the United States. The Food and Drug Administration (FDA) has given the green light to once-a-day Opill, which will soon be available without a prescription, making it the first contraceptive medication to be accessible directly from retail shelves, similar to aspirin and eyedrops. Perrigo, the Ireland-based manufacturer, plans to begin shipping the pill early next year, and there will be no age restrictions on sales.

Traditionally, hormone-based birth control pills have been the most widely used contraceptive method in the U.S. since the 1960s. However, until now, all of these pills required a prescription. Medical societies and women's health groups have advocated for increased access to these medications for years, particularly considering that approximately 45% of the 6 million annual pregnancies in the U.S. are unintended. Certain demographics, such as teens, women of colour, and those with low incomes, have faced additional barriers in obtaining prescriptions, including costs, time off from work, and childcare arrangements.

The approval of Opill is seen as a significant step forward in contraceptive care accessibility, potentially helping individuals overcome the hurdles that exist with prescription-based methods. Perrigo expects Opill to become an essential option for the estimated 15 million U.S. women who currently use no birth control or less effective methods.

However, the extent of the impact will depend on the pill's pricing, which Perrigo plans to announce later this year. Women's advocates emphasise that the goal of making birth control pills available over the counter is to improve access, and cost should not be a prohibitive factor. While over-the-counter medicines are generally more affordable than prescription drugs, they are often not covered by insurance. Advocates are urging the federal government to make a regulatory change that would require insurers to cover over-the-counter birth control.

The FDA's approval of Opill provides women in the U.S. with another birth control option amid the ongoing legal and political battles over reproductive health, including last year's reversal of Roe v. Wade, which has had significant implications for abortion access nationwide. Opill's approval, however, is unrelated to the ongoing court battles over the abortion pill mifepristone. Despite some concerns raised by FDA scientists about certain underlying medical conditions and drug usage, the FDA's decision applies specifically to Opill, which belongs to an older class of contraceptives known as minipills, generally associated with fewer side effects.

While this approval is a significant milestone, women's health advocates hope it will pave the way for more over-the-counter birth control options and, potentially, for abortion pills to follow suit. An FDA advisory panel unanimously supported the switch to over-the-counter status for Opill during a hearing in May, where public speakers rallied in favour of the approval.

Click here to read the original news story.